Aspirin Strategy Group calls for advisory committee review of new aspirin indications.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN PROFESSIONAL INDICATIONS REVIEW BY FDA ADVISORY COMMITTEE URGED by Charles Hennekens, MD/PhD, Harvard Medi-cal School, in a July 18 letter to OTC Drug Division Director Debra Bowen, MD. The letter asserts that "a meeting of the Cardiovascular and Renal Drugs Advisory Committee should be scheduled as expeditiously as possible to make recommendations concerning any additional cardiovascular uses of aspirin that are justified."